Statin myopathy – rarity or reality?

Czech version

Authors: D. Pella
Authors‘ workplace: III. interná klinika Lekárskej fakulty UPJŠ a UN L. Pasteura Košice, Slovenská republika, prednosta prof. MU Dr. Daniel Pella, PhD.
Published in: Vnitř Lék 2010; 56(9): 972-976
Category: 60th Birthday - Andrej Dukat MD, Csc., FESC

Overview

Statins are the most effective drugs for reducing LDL‑cholesterol and have strong evidence based medicine documented by significant reduction of cardiovascular events in wide variety of patients. Despite this fact, they are still underused in common clinical practice. Many physicians have expressed concern about potential adverse effects, particularly severe muscle toxicity, which is an impediment to appropriate statin use. The clinical symptoms of statin myopathy include myalgia or muscle weakness, tiredness, cramps and/ or creatinkinase activity increases (CK). Because hypercholesterolaemia is usually asymptomatic, any unwanted effect of drug used for its management can undermine adherence. Therefore it is very important to evaluate myopathy magnitude, prompt and rational individual management, and if applicable, restart of lipid‑ lowering therapy as soon as possible with regard to its type, dose and concomitant treatment.

Key words:
statin myopathy – statin‑associated myopathy – myalgia – myositis – rhabdomyolysis

Sources

1. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol‑ lowering treatment: prospective meta‑analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267– 1278.

2. Hughes DA, Walley T. Predicting “real world” effectiveness by integrating adherence with pharmacodynamic modeling. Clin Pharmacol Ther 2003; 74: 1– 8.

3. Kiortsis DN, Giral P, Bruckert E et al. Factors associated with low compliance with lipid‑ lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000; 25: 445– 451.

4. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401– 408.

5. Siddiqi SA, Thompson PD. How do you treat patients with myalgia who take statins? Curr Atheroscler Rep 2009; 11: 9– 14.

6. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007; 9: 389– 396.

7. Pasternak RC, Smith SC Jr, Bairey‑ Merz CN et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/ AHA/ NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567– 572.

8. McKenney JM, Davidson MH, Jacobson TA et al. National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97 (Suppl 8A): 89C– 94C.

9. Moosmann B, Behl C. Selenoprotein synthesis and side effects of statins. Lancet 2004; 363: 892– 894.

10. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin‑associated myotoxicity. Curr Opin Pharmacol 2008; 8: 333– 338.

11. Draeger A, Monastyrskaya K, Mohaupt M et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006; 210: 94– 102.

12. Duncan AJ, Hargreaves IP, Damian MS et al. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment. Toxicol Mech Methods 2009; 19: 44– 50.

13. Päivä H, Thelen KM, Van Coster R et al. High‑dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78: 60– 68.

14. Hanai J, Cao P, Tanksale P et al. The muscle‑ specific ubiquitin ligase atrogin‑1/ MAFbx mediates statin‑induced muscle toxicity. J Clin Invest 2007; 117: 3940– 3951.

15. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8: 373– 418.

16. Galli F, Iuliano L. Do statins cause myopathy by lowering vitamin E levels? Med Hypotheses 2010; 74: 707– 709.

17. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781– 1790.

18. Buettner C, Davis RB, Leveille SG et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008; 23: 1182– 1186.

19. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high‑dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403– 414.

20. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Eng J Med 2002; 346: 539– 540.

21. Smogorzewski M. The myopathy of statins. J Ren Nutr 2005; 15: 87– 93.

22. Chatzizisis YS, Koskinas KC, Misirli G et al. Risk factors and drug interactions predisposing to statin‑induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171– 187.

23. Ghatak A, Faheemb O, Thompson PD. The genetics of statin‑induced myopathy. Atherosclerosis 2010; 210: 337– 343.

24. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin‑induced myopathy – a genome wide study. N Engl J Med 2008; 359: 789– 799.

25. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin‑induced side effects. J Am Coll Cardiol 2009; 54: 1609– 1616.

26. Caso G, Kelly P, McNurlan MA et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99: 1409– 1412.

27. Young JM, Florkowski CM, Molyneux SL et al. Effect of coenzyme Q(10) supplementation on simvastatin‑induced myalgia. Am J Cardiol 2007; 100: 1400– 1403.

28. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end‑points of “Q‑ symbio” – a multinational trial. Biofactors 2003; 18: 79– 89.

29. Molyneux SL, Florkowski CM, George PM et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 2008; 52: 1435– 1441.

30. Fedačko J, Pella D, Rybár R et al. Coenzyme Q10 and selenium in the treatment of statin‑associated myopathy. Results of randomized double‑blind clinical study. Eur Heart J 2009; Suppl 30: Abstract 234.